Share-based Payment Arrangement, Expense of Vera Therapeutics, Inc. from 31 Mar 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Vera Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Sep 2025.
  • Vera Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $9,745,000, a 74% increase year-over-year.
  • Vera Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $33,178,000, a 86% increase year-over-year.
  • Vera Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $20,802,000, a 81% increase from 2023.
  • Vera Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $11,493,000, a 29% increase from 2022.
  • Vera Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $8,887,000, a 195% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Vera Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $33,178,000 $9,745,000 +$4,157,000 +74% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $29,021,000 $9,472,000 +$4,599,000 +94% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $24,422,000 $7,744,000 +$3,620,000 +88% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $20,802,000 $6,217,000 +$2,996,000 +93% 01 Oct 2024 31 Dec 2024 10-K 28 Feb 2025 2024 FY
Q3 2024 $17,806,000 $5,588,000 +$2,665,000 +91% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $15,141,000 $4,873,000 +$2,191,000 +82% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $12,950,000 $4,124,000 +$1,457,000 +55% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 $11,493,000 $3,221,000 +$473,000 +17% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
Q3 2023 $11,020,000 $2,923,000 +$471,000 +19% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $10,549,000 $2,682,000 +$657,000 +32% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $9,892,000 $2,667,000 +$1,005,000 +60% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q4 2022 $8,887,000 $2,748,000 +$1,786,000 +186% 01 Oct 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
Q3 2022 $7,101,000 $2,452,000 +$1,519,000 +163% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $5,582,000 $2,025,000 +$1,312,000 +184% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $4,270,000 $1,662,000 +$1,258,000 +311% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $3,012,000 $962,000 +$819,000 +573% 01 Oct 2021 31 Dec 2021 10-K 28 Mar 2023 2022 FY
Q3 2021 $2,193,000 $933,000 +$878,000 +1596% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $1,315,000 $713,000 +$641,000 +890% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $674,000 $404,000 +$343,000 +562% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $331,000 $143,000 01 Oct 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
Q3 2020 $55,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $72,000 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2
Q1 2020 $61,000 01 Jan 2020 31 Mar 2020 10-Q 24 Jun 2021 2021 Q1

Vera Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $20,802,000 +$9,309,000 +81% 01 Jan 2024 31 Dec 2024 10-K 28 Feb 2025 2024 FY
2023 $11,493,000 +$2,606,000 +29% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
2022 $8,887,000 +$5,875,000 +195% 01 Jan 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
2021 $3,012,000 +$2,681,000 +810% 01 Jan 2021 31 Dec 2021 10-K 28 Mar 2023 2022 FY
2020 $331,000 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.